December 1, 2025

FINAL NOTICE: NATPARA® SPECIAL USE PROGRAM CLOSES DECEMBER 31, 2025

Dear Healthcare Provider:

This is the final notice that Takeda, in alignment with the U.S. FDA, will close the NATPARA® Special Use Program (SUP) on December 31, 2025. This means that **no NATPARA shipments will be sent after December 31, 2025**. This decision follows the previously communicated global manufacturing discontinuation of NATPARA in December 2024. You are receiving this message because you are on file as the prescriber for at least one patient currently enrolled in the SUP.

Transitioning To Alternate Treatment

It is essential to meet with your patient(s) as soon as possible to develop alternate treatment plans, including, if appropriate for your patient(s), potential transition to the FDA-approved treatment for adult patients with hypoparathyroidism. The decision as to whether this treatment is appropriate for your patient(s) entails an HCP-patient discussion and eventual decision. While Takeda cannot recommend nor endorse this treatment, we are committed to ensuring the relevant information is easily accessible to support informed decision-making for the benefit of patients. The U.S. Product Information (USPI) for this therapy is available at: https://ascendispharma.us/products/pi/yorvipath/yorvipath_pi.pdf. Further contact information can be found at: https://ascendispharma.us/contact-us/.

Safety Considerations – Abrupt Treatment Withdrawal

We would like to remind you that abrupt discontinuation of NATPARA can result in severe hypocalcemia – please review Section 2.6 (NATPARA Dose Interruption or Discontinuation) and Section 5.4 (Warnings and Precautions: Hypocalcemia) in the NATPARA Full Prescribing Information. It is very important to closely monitor serum calcium levels and observe for signs and symptoms of hypocalcemia in these patients while carefully adjusting active vitamin D and supplemental calcium doses. Some patients may require higher doses of active vitamin D and supplemental calcium than doses required prior to starting NATPARA. Notify patients of the risk of severe hypocalcemia when discontinuing NATPARA, the need for close follow-up, and the importance of seeking urgent medical attention if they experience signs or symptoms of hypocalcemia.

Special Use Program Requirements

Please remind your patient(s) that all used and unused NATPARA cartridges must be returned after SUP closure, following the established return procedures.

Thank you for your urgent action.

Sincerely,

Tom Koutsavlis, MD, FRCPC
Head, US Medical

This communication is not intended as a complete description of the benefits and risks related to the use of NATPARA. Please visit https://www.shirecontent.com/PI/PDFs/Natpara_USA_ENG.pdf to review the full Prescribing Information and Medication Guide.